AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02123069
Drug: Nitroprusside
RxNorm normalized name: Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
Trial: NCT02123069
Drug: Nitroprusside and phenylephrine
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
Trial: NCT02323139
Drug: Azacitidine and LDE255
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
Trial: NCT01726335
Drug: Risperidone prolonged release
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
Trial: NCT03068910
Drug: Micronized progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
Trial: NCT02264873
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
Trial: NCT04090086
Drug: JNJ-53718678
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.
Trial: NCT04090086
Drug: JNJ-64417184
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.
Trial: NCT01375569
Drug: TRC105
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN ENDOGLIN) (HUMAN-MUS MUSCULUS MONOCLONAL TRC105 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TRC105 .KAPPA.-CHAIN, DIMER
DrugBank: Carotuximab (DB06322)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02496754
Drug: GnRH-a
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
Trial: NCT02496754
Drug: GnRH-anta
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In control group, patients use GnRH-antagonist. Patients' serum or follicle fluid will be collected if needed.
Trial: NCT00309413
Drug: Placebo/Cannabidiol
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg/day, oral, capsules, 2 weeks, than cross-over
Trial: NCT00309413
Drug: Cannabidiol/Placebo
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg/day, oral, capsules, 2 weeks, than cross-over
Trial: NCT00868179
Drug: Pradax
RxNorm normalized name: Pradaxa
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
Trial: NCT02496221
Drug: Albiglutide 50 mg
RxNorm normalized name: albiglutide 50 MG in 0.5 ML Pen Injector
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
Trial: NCT02496221
Drug: CCK (Kinevac)
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
Trial: NCT01557452
Drug: Givinostat
RxNorm normalized name: givinostat
DrugBank: Givinostat (DB12645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients
Trial: NCT00192088
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00192088
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03324581
Drug: OPC-64005
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-64005 film coated tablets
Trial: NCT03324581
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine gelatin capsules
Trial: NCT00796289
Drug: GnRH iontophoretic transdermal Lutrepatch
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
Trial: NCT00796289
Drug: GnRH iontophoretic transdermal Lutrepatch
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
Trial: NCT00796289
Drug: GnRH iontophoretic transdermal Lutrepatch
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
Trial: NCT00796289
Drug: clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 50 mg daily for 5 days
Trial: NCT00796289
Drug: placebo clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, taken for 5 days
Trial: NCT01113476
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of 50 mg/m\^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
Trial: NCT01113476
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of 5 mg/m\^2 on Day 1 + 15 every 28 days (+/- 2 days)
Trial: NCT01113476
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
Trial: NCT00746447
Drug: mesalamine granules
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
Trial: NCT00746447
Drug: mesalamine granules
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
Trial: NCT00746447
Drug: mesalamine granules
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
Trial: NCT02707159
Drug: Nab paclitaxel / gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
Trial: NCT01281527
Drug: Paliperidone Palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 - 150 mg eq. every 30 days
Trial: NCT03134196
Drug: Masked Oral Valacyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Valacyclovir 1000 mg/day
Trial: NCT02945150
Drug: elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those \<75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV).
Trial: NCT02648997
Drug: Nivolumab - 240 mg
RxNorm normalized name: nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 240 mg every 2 weeks
Trial: NCT02648997
Drug: Ipilimumab - 1 mg/kg
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 mg/kg every 3 weeks
Trial: NCT02648997
Drug: Nivolumab - 480 mg
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 480 mg once every 4 weeks
Trial: NCT02648997
Drug: Nivolumab - 3 mg/kg
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg/kg every 3 weeks
Trial: NCT02586402
Drug: pegol-Sihematide
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02586402
Drug: Epoetin Alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01030328
Drug: TriLipix
RxNorm normalized name: Trilipix
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
Trial: NCT01076075
Drug: Sitagliptin phosphate
RxNorm normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
Trial: NCT01076075
Drug: Comparator: placebo to pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
Trial: NCT01076075
Drug: Comparator: placebo to Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
Trial: NCT01076075
Drug: Comparator: pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
Trial: NCT01076075
Drug: Glimepiride or gliclazide
RxNorm normalized name: gliclazide
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
Trial: NCT01076075
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin
Trial: NCT01076075
Drug: Pioglitazone rescue therapy
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
Trial: NCT00391261
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: open-label, flexible dosing
Trial: NCT00817284
Drug: bevacizumab and Irinotecan and radiotherapy
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Bevacizumab 10 mg/kg is administered on days 1 and 15.~* Irinotecan:~* Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~* Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~* During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.
Trial: NCT00817284
Drug: Bevacizumab and Temozolomide and radiotherapy
RxNorm normalized name: Temozolomide
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.
Trial: NCT04316598
Drug: Cannabis placebo
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a total of 4 inhaled doses of cannabis placebo (THC \<0,2%) in 3 days.~Placebo cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing cannabinoids \<0.2%. To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of cannabis placebo.
Trial: NCT02634203
Drug: Riociguat
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
Trial: NCT01483833
Drug: Iferanserin
RxNorm normalized name: Iferanserin
DrugBank: Iferanserin (DB11686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
Trial: NCT00130000
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02874768
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 \~ 0.7 mcg/kg/h)
Trial: NCT02874768
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 \~ 1.6 mg/kg/h)
Trial: NCT04432012
Drug: Dexamethasone Sodium Phosphate 4 mg/ml intravenous
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perioperative intravenous injection of 3 ml of solution (9mg of dexamethasone)
Trial: NCT04432012
Drug: Dexamethasone Sodium Phosphate 4 mg/ml intra-articular
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perioperative intra-articular injection of 3 ml of solution (9mg of dexamethasone)
Trial: NCT00193193
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00193193
Drug: Estramustine
RxNorm normalized name: Estramustine
DrugBank: Estramustine (DB01196)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00193193
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05538819
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride 1-4 mg/day
Trial: NCT00548587
Drug: E5555
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01598571
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 50 mg tablet
Trial: NCT01598571
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose
Trial: NCT04126070
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.
Trial: NCT04126070
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
Trial: NCT03582800
Drug: STS
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: M0-M6 (run-in phase): medical care and follow-up as usual~M6-M12 (STS phase):~* Patients with iPPSD2 will be treated with subcutaneous infusion using a portable pump.~* Patients with dermatomyositis or systemic sclerosis will be treated with repeated injections every two weeks.~Patients will receive a maximal total number of 11 STS injections. M12: final visit (V5): clinical evaluation, photograph and CT scan of the treated lesion, pain and quality of life evaluation.
Trial: NCT05025228
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol given orally or intravenously
Trial: NCT02145403
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels.
Trial: NCT02145403
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
Trial: NCT00566631
Drug: Paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
Trial: NCT02405104
Drug: chlorzoxazone
RxNorm normalized name: Chlorzoxazone
DrugBank: Chlorzoxazone (DB00356)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATC-code: M03BB03
Trial: NCT00109629
Drug: VRC-HIVDNA016-00-VP
RxNorm normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03381274
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.
Trial: NCT04529772
Drug: acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigational Product
Trial: NCT02182011
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02182011
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no